Interferon-induced depression in patients with hepatitis C: An epidemiologic study

Revista da Associacao Medica Brasileira

Volumn 60, Issue 1, 2014, Pages 35-39

  De Medeiros, Lucas Pereira Jorge ^a,b,c,f   Kayo, Monica ^d   Medeiros, Renata Barboza Vianna ^e   Lima, Mario Barreto Correa ^a   Mello, Carlos Eduardo Brandão ^a,e  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Souza Marques Medical School   (Brazil)

^c University Center of Volta Redonda RJ   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^f General Hospital of Santa Casa de Misericórdia Do Rio de Janeiro   (Brazil)

Author keywords

Depression; HCV; Hepatitis.; Interferon alpha; Pegylated interferon alpha 2b

Indexed keywords

ANTIDEPRESSANT AGENT; BILIRUBIN; CREATININE; HEMOGLOBIN; NEUROLEPTIC AGENT; PEGINTERFERON ALPHA2B; RIBAVIRIN; SERUM ALBUMIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGED; ALCOHOL ABUSE; ANTIVIRAL THERAPY; ARTICLE; BECK DEPRESSION INVENTORY; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; FEMALE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; INCIDENCE; MALE; MEDICAL HISTORY; MIDDLE AGED; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME TO TREATMENT; TREATMENT DURATION; ADDICTION; ALCOHOLISM; BRAZIL; CHEMICALLY INDUCED; COMPLICATION; DRUG COMBINATION; PSYCHOMETRY; TIME;

ADULT; AGED; ALCOHOL-RELATED DISORDERS; ANTIVIRAL AGENTS; BRAZIL; DEPRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INCIDENCE; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; PSYCHOMETRICS; RECOMBINANT PROTEINS; RIBAVIRIN; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 84927171558     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/1806-9282.60.01.009     Document Type: Article

References (23)

1. World Health Organizartion (WHO). Hepatitis C. Fact sheet n.164. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/index.html#.
2. Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry. 2003;25:34-8.
3. Martin-Santos R, Diez-Quevedo C, Castellvi P, Navines R, Miquel M, Masnou H, Soler A, Ardevol M, Garcia F, Galeras JA, Planas R, Sola R. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther. 2008;27:257-65.
4. Quarantini LC, Bressan RA, Galvao A, Batista-Neves S, Parana R, Miranda-Scippa A. Incidence of psychiatric side effects during pegylated interferonalpha retreatment in nonresponder hepatitis C virus-infected patients. Liver Int. 2007;27:1098-102.
5. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry. 2005;66:41-8.
6. Reichenberg A, Gorman JM, Dieterich DT. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS. 2005;19(Suppl 3):S174-8.
7. Batista-Neves S, Quarantini LC, Galvao-de Almeida A, Cardeal M, Lacerda AL, Parana R, Reis de-Oliveira I, Bressan RA, Miranda-Scippa A. Impact of psychiatric disorders on the quality of life of brazilian HCV-infected patients. Braz J Infect Dis. 2009;13:40-3.
8. Dan AA, Martin LM, Crone C, Ong JP, Farmer DW, Wise T, Robbins SC, Younossi ZM. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol. 2006;44:491-8.
9. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-71.
10. Radloff LS. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Meas. 1977:385-401.
11. Schafer A, Wittchen HU, Seufert J, Kraus MR. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review. Int J Methods Psychiatr Res. 2007;16:186-201.
12. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive therapy of depression. New York: Guilford; 1979.
13. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev. 1988;8:77-100.
14. Castera L, Zigante F, Bastie A, Buffet C, Dhumeaux D, Hardy P. Incidence of interferon alfa-induced depression in patients with chronic hepatitis C. Hepatology. 2002;35:978-9.
15. Pavlovic Z, Delic D, Maric NP, Vukovic O, Jasovic-Gasic M. Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study. Psychiatr Danub. 2011;23:370-7.
16. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology. 2002;35:704-8.
17. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82.
18. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65.
19. Neri S, Pulvirenti D, Bertino G. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b. Clin Drug Investig. 2006;26:655-62.
20. Udina M, Castellvi P, Moreno-Espana J, Navines R, Valdes M, Forns X, Langohr K, Sola R, Vieta E, Martin-Santos R. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry. 2012;73:1128-38.
21. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD, Meyers CA, Howell CD. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7:942-7.
22. Galvao-de Almeida A, Guindalini C, Batista-Neves S, de Oliveira IR, Miranda-Scippa A, Quarantini LC. Can antidepressants prevent interferon-alphainduced depression? A review of the literature. Gen Hosp Psychiatry. 2010;32:401-5.
23. Kraus MR, Schafer A, Schottker K, Keicher C, Weissbrich B, Hofbauer I, Scheurlen M. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut. 2008;57:531-6.